• PDF: Delivered by email usually within 48 UK business hours.

Exiqon AS (EXQ)
Product Pipeline Analysis

  • Publication Date:November 2012
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:42

Exiqon AS (EXQ) Product Pipeline Analysis

Summary

Exiqon AS (Exiqon) is a Denmark-based biotechnology company. It undertakes the development, manufacture and distribution of products for the diagnosis of cancer and gene expression analysis. The company develops its products through the combination of leading edge scientific expertise in gene expression with its proprietary Locked Nucleic Acids (LNA) technology. Exiqon's product line includes miRCURY RNA Isolation kits, microRNA, miRCURY LNA Universal RT microRNA PCR, mRNA PCR, In Situ hybridization, mRNA isolation and reagents. In addition to this, it also manufactures numerous types of probes used in the procedure. The company provides its products to drug developers, life science researchers and physicians developing personalized treatment for cancer in the medical healthcare industry. It operates in Denmark, the US, Australia, China, Italy, Japan, Korea, and New Zealand. Exiqon is headquartered in Vedbaek, Denmark.

The company's strategy is to enhance its position as a leading biotechnology company through the development of microRNA research and diagnostic tools with leading-edge products and services based on its proprietary LNA detection technology.

This report is a source for data, analysis and actionable intelligence on the Exiqon AS portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

  • Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
  • Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
  • Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
  • Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
  • Data on relevant clinical trials and product patent details, wherever applicable.
  • Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Develop competition strategies by identifying the status and likely launch of your competitors' pipeline products through review of the clinical trials, stage and phase of development, etc.- Which are the next high-value products that your competitor would add in its portfolio? - identify, understand and capitalize.
  • Section
    • Exiqon A/S - Business Description
    • Key Facts
    • Exiqon A/S - Major Products and Services
    • Exiqon A/S Pipeline Products by Equipment Type
    • Exiqon A/S Pipeline Products by Development Stage
    • Exiqon A/S Pipeline Products by Therapy Area
    • Exiqon A/S Pipeline Products by Milestone Summary
    • Colon Cancer Recurrence Test
    • Colon Cancer Recurrence Test Product Status
    • Colon Cancer Recurrence Test Product Description
    • miRNA Assay - Colorectal Cancer
    • miRNA Assay - Colorectal Cancer Product Status
    • miRNA Assay - Colorectal Cancer Product Description
    • miRNA Assay - Colorectal Cancer Product Milestone
    • Product Institution Details
    • miRNA Test - Endometrial Cancer
    • miRNA Test - Endometrial Cancer Product Status
    • miRNA Test - Endometrial Cancer Product Description
    • miRNA Test - Endometrial Cancer Product Patent Details
    • miRNA Test - Lung Cancer
    • miRNA Test - Lung Cancer Product Status
    • miRNA Test - Lung Cancer Product Description
    • miRNA Test - Lung Cancer Product Patent Details
    • miRNAbiomarker - Cancer of Unknown Primary
    • miRNAbiomarker - Cancer of Unknown Primary Product Status
    • miRNAbiomarker - Cancer of Unknown Primary Product Description
    • miRNAbiomarker - Cancer of Unknown Primary Product Patent Details
    • Exiqon A/S - Key Competitors
    • Exiqon A/S - Key Employees
    • Exiqon A/S - Key Employee Biographies
    • Exiqon A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Recent Developments
    • Exiqon A/S, Recent Developments
    • Jun 14, 2012: Exiqon Launches Bioinformatics Tool For Design And Selection Of LNA Enhanced qPCR Assays For Combined Analysis Of Messenger RNA, MicroRNA And Other ncRNA
    • Oct 10, 2011: Exiqon Launches New Products For R&D Of LNA Based Drugs
    • Oct 07, 2011: Exiqon Completes Litigation Against Santaris Pharma
    • Sep 09, 2011: Exiqon And AROS Applied Biotechnology Sign Center Of Excellence Agreement
    • May 23, 2011: Exiqon Announces Presentation Of Results At 2011 ASCO Annual Meeting In Chicago
    • May 03, 2011: Exiqon Launches Pick-&-Mix microRNA qPCR Arrays
    • Apr 12, 2011: Exiqon Expands Distributor Network
    • Apr 04, 2011: Exiqon Reports Positive Results On Early Detection Of Colorectal Cancer In Blood
    • Feb 08, 2011: Exiqon To Present New Data At AACR Conference
    • Jan 12, 2011: Exiqon Releases Second Generation Human microRNA Inhibitor Libraries
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Exiqon A/S, Key Facts
    • Exiqon A/S Key Pipeline Products by Equipment Type
    • Exiqon A/S Key Pipeline Products by Therapy Area
    • Exiqon A/S Key Pipeline Products by Development Stage
    • Exiqon A/S, Key Facts
    • Exiqon A/S, Major Products and Services
    • Exiqon A/S Number of Pipeline Products by Equipment Type
    • Exiqon A/S Pipeline Products by Equipment Type
    • Exiqon A/S Number of Pipeline Products by Development Stage
    • Exiqon A/S Pipeline Products by Development Stage
    • Exiqon A/S Number of Pipeline Products by Therapy Area
    • Exiqon A/S Pipeline Products by Therapy Area
    • Exiqon A/S Number of Pipeline Products By Milestone Summary
    • Exiqon A/S Pipeline Products by Milestone Summary
    • Colon Cancer Recurrence Test - Product Status
    • Colon Cancer Recurrence Test - Product Description
    • miRNA Assay - Colorectal Cancer - Product Status
    • miRNA Assay - Colorectal Cancer - Product Description
    • miRNA Assay - Colorectal Cancer - Product Milestone
    • miRNA Test - Endometrial Cancer - Product Status
    • miRNA Test - Endometrial Cancer - Product Description
    • miRNA Test - Endometrial Cancer - Patent Details1
    • miRNA Test - Endometrial Cancer - Patent Details2
    • miRNA Test - Endometrial Cancer - Patent Details3
    • miRNA Test - Endometrial Cancer - Patent Details4
    • miRNA Test - Endometrial Cancer - Patent Details5
    • miRNA Test - Endometrial Cancer - Patent Details6
    • miRNA Test - Lung Cancer - Product Status
    • miRNA Test - Lung Cancer - Product Description
    • miRNA Test - Lung Cancer - Patent Details1
    • miRNA Test - Lung Cancer - Patent Details2
    • miRNA Test - Lung Cancer - Patent Details3
    • miRNA Test - Lung Cancer - Patent Details4
    • miRNA Test - Lung Cancer - Patent Details5
    • miRNA Test - Lung Cancer - Patent Details6
    • miRNAbiomarker - Cancer of Unknown Primary - Product Status
    • miRNAbiomarker - Cancer of Unknown Primary - Product Description
    • miRNAbiomarker - Cancer of Unknown Primary - Patent Details1
    • miRNAbiomarker - Cancer of Unknown Primary - Patent Details2
    • miRNAbiomarker - Cancer of Unknown Primary - Patent Details3
    • miRNAbiomarker - Cancer of Unknown Primary - Patent Details4
    • miRNAbiomarker - Cancer of Unknown Primary - Patent Details5
    • miRNAbiomarker - Cancer of Unknown Primary - Patent Details6
    • Exiqon A/S, Key Employees
    • Exiqon A/S, Key Employee Biographies
    • Exiqon A/S, Other Locations
    • Exiqon A/S, Subsidiaries
    • Exiqon A/S Pipeline Products by Equipment Type
    • Exiqon A/S Pipeline Products by Development Stage
    • Exiqon A/S Pipeline Products by Therapy Area
    • Exiqon A/S Pipeline Products by Milestone Summary
+44 20 8816 8548

Ask a question about Exiqon AS (EXQ)

Enter the characters you see in the picture below
Captcha